EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cisplatin Promotes Immunosuppression in Ovarian Cancer by Enhancing miR‐181a‐5p‐Enriched Extracellular Vesicles to Drive Regulatory T Cell Differentiation

Liyan Zheng, Sijia Mu, Mingxue Liu, Panmin Lei, Jingchen Zhang, Yuting Dai, Chenxi He, Fengli Qu iD, Weihong Tan

Journal of Extracellular Vesicles · 2026-04 · 15 (4)

DOI: 10.1002/jev2.70261 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, online erschienen am 07.04.2026. Verfasst von Liyan Zheng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Cisplatin, MicroRNAs, Extracellular Vesicles, Ovarian Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Zhejiang Provincial Health Commission Research Foundation, foundation of Hangzhou Institute of Medicine, CAS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although cisplatin (CDDP) is widely employed in combination immunotherapy, no CDDP‐based regimen has shown a survival benefit when treating the ovarian cancers. This is mainly because the impact of CDDP on immunotherapy is not fully understood. A critical gap concerns how CDDP reshape the tumour microenvironment, especially through extracellular vesicles (EVs)‐mediated communication. In this work, using human and murine ovarian cancer cells as a model, we demonstrate that CDDP boosts the secretion of EVs from cancer cells, while exerting no such effect on non‐cancerous cells. These CDDP‐induced tumour‐derived EVs, in turn, drive the differentiation of CD4 + T cells towards immunosuppressive regulatory T cells (T reg cells), which are known to limit the efficacy of immunotherapy. Based on next‐generation sequencing, a significant enrichment of miR‐181a‐5p was identified in CDDP‐induced tumour‐derived EVs, and further functional studies confirmed that this microRNA promoted T reg cell differentiation via suppressing sirtuin 1 (SIRT1), a key regulator of the transcription factor forkhead box protein P3 (FOXP3). Importantly, inhibition of miR‐181a‐5p abrogated the T reg ‐promoting effect of CDDP‐induced tumour‐derived EVs, a finding further validated in vivo , where blockade of miR‐181a‐5p not only impaired T reg differentiation but also restored T‐cell‐mediated antitumour immunity and restrained tumour growth. Together, these findings uncover a previously unrecognised mechanism by which CDDP exacerbates immunosuppression via miR‐181a‐5p‐enriched EVs and suggest that targeting this pathway could improve the therapeutic efficacy of combination immunotherapy in ovarian cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinMicroRNAsExtracellular VesiclesOvarian NeoplasmsT-Lymphocytes, RegulatoryFemaleAnimalsHumansMiceCell DifferentiationCell Line, TumorForkhead Transcription FactorsSirtuin 1Tumor MicroenvironmentImmunosuppression TherapyAntineoplastic AgentsImmune Tolerance

Stichwörter der Autor:innen

cisplatinextracellular vesiclesmicroRNAsovarian cancer

Substanzen

CisplatinMicroRNAsMIrn181 microRNA, humanForkhead Transcription FactorsSirtuin 1Antineoplastic Agents

Autor:innen und Institutionen

  • Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
  • Molecular Science and Biomedicine Laboratory (MBL), State, Key Laboratory of Chemo/BioSensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha, Hunan, China.
  • School of Science, Tianjin University, Tianjin, China.
  • College of Chemistry and Chemical Engineering, Qufu Normal University, Qufu, Shandong, China.

ORCID-Profile: Fengli Qu

Förderung

  • National Natural Science Foundation of China
  • Zhejiang Provincial Health Commission Research Foundation
  • foundation of Hangzhou Institute of Medicine, CAS
  • Leading Innovative and Entrepreneur Team Introduction Program of Zhejiang Province
  • Pioneer Research and Development Program of Zhejiang
  • Research Funds of Hangzhou Institute for Advanced Study, UCAS

Zitieren

APA

Zheng, L., Mu, S., Liu, M., Lei, P., Zhang, J., Dai, Y., He, C., Qu, F., & Tan, W. (2026). Cisplatin Promotes Immunosuppression in Ovarian Cancer by Enhancing miR‐181a‐5p‐Enriched Extracellular Vesicles to Drive Regulatory T Cell Differentiation. Journal of Extracellular Vesicles, 15(4). https://doi.org/10.1002/jev2.70261

Vancouver

Zheng L, Mu S, Liu M, Lei P, Zhang J, Dai Y, et al. Cisplatin Promotes Immunosuppression in Ovarian Cancer by Enhancing miR‐181a‐5p‐Enriched Extracellular Vesicles to Drive Regulatory T Cell Differentiation. Journal of Extracellular Vesicles. 2026;15(4). doi:10.1002/jev2.70261

BibTeX
@article{Zheng2026,
  author = {Zheng, Liyan and Mu, Sijia and Liu, Mingxue and Lei, Panmin and Zhang, Jingchen and Dai, Yuting and He, Chenxi and Qu, Fengli and Tan, Weihong},
  title = {Cisplatin Promotes Immunosuppression in Ovarian Cancer by Enhancing miR‐181a‐5p‐Enriched Extracellular Vesicles to Drive Regulatory T Cell Differentiation},
  journal = {Journal of Extracellular Vesicles},
  year = {2026},
  volume = {15},
  number = {4},
  doi = {10.1002/jev2.70261}
}
Kostenlos starten →